Analysts expect Neurocrine Biosciences (NASDAQ:NBIX) to report $65.97 million in sales for the current quarter, Zacks Investment Research reports. Five analysts have provided estimates for Neurocrine Biosciences’ earnings, with the highest sales estimate coming in at $71.04 million and the lowest estimate coming in at $59.20 million. The company is expected to report its next quarterly earnings results on Tuesday, May 8th.
On average, analysts expect that Neurocrine Biosciences will report full year sales of $373.62 million for the current year, with estimates ranging from $327.30 million to $420.00 million. For the next financial year, analysts anticipate that the company will report sales of $615.22 million per share, with estimates ranging from $563.84 million to $648.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings data on Tuesday, February 13th. The company reported $0.07 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.18 by ($0.11). The company had revenue of $94.52 million for the quarter, compared to the consensus estimate of $94.00 million. During the same quarter last year, the business posted ($0.51) EPS.
In related news, insider Dimitri E. Grigoriadis sold 86,368 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $78.32, for a total value of $6,764,341.76. Following the completion of the sale, the insider now owns 154,717 shares of the company’s stock, valued at $12,117,435.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin Charles Gorman sold 105,983 shares of the firm’s stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $80.25, for a total value of $8,505,135.75. Following the completion of the sale, the chief executive officer now directly owns 339,482 shares of the company’s stock, valued at approximately $27,243,430.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 361,761 shares of company stock valued at $29,576,784. Insiders own 4.30% of the company’s stock.
Hedge funds have recently made changes to their positions in the stock. Crow Point Partners LLC purchased a new stake in Neurocrine Biosciences in the fourth quarter worth $145,000. American International Group Inc. purchased a new stake in Neurocrine Biosciences in the fourth quarter worth $161,000. M&T Bank Corp purchased a new stake in Neurocrine Biosciences in the fourth quarter worth $202,000. Mission Wealth Management LP purchased a new stake in Neurocrine Biosciences in the fourth quarter worth $204,000. Finally, The Manufacturers Life Insurance Company lifted its stake in Neurocrine Biosciences by 7.8% in the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after acquiring an additional 193 shares during the period.
Shares of NASDAQ NBIX opened at $78.18 on Tuesday. Neurocrine Biosciences has a one year low of $41.76 and a one year high of $92.98. The company has a debt-to-equity ratio of 0.99, a current ratio of 10.20 and a quick ratio of 10.20.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by Week Herald and is the sole property of of Week Herald. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://weekherald.com/2018/04/20/neurocrine-biosciences-nbix-expected-to-post-quarterly-sales-of-65-97-million.html.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.